SLC5A2 and hydrops fetalis: In 2022, the American Heart Association (AHA), American College of Cardiology (ACC), and the Heart Failure Society of America (HFSA) recommended SGLT2 inhibitors as Class I (Level A) treatment for symptomatic chronic HFrEF in order to lower CV mortality and hospitalizations due to HF.